KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Income: 2011-2025

Historic Operating Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$60.2 million.

  • Supernus Pharmaceuticals' Operating Income fell 247.46% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 162.33%. This contributed to the annual value of $81.7 million for FY2024, which is 1649.93% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Operating Income of -$60.2 million as of Q3 2025, which was down 596.10% from $12.1 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Operating Income peaked at $40.8 million during Q3 2024, and registered a low of -$60.2 million during Q3 2025.
  • Moreover, its 3-year median value for Operating Income was $5.2 million (2023), whereas its average is $1.6 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Operating Income crashed by 255.01% in 2023 and then surged by 2,249.10% in 2024.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Operating Income stood at $6.1 million in 2021, then skyrocketed by 463.04% to $34.3 million in 2022, then tumbled by 102.90% to -$996,000 in 2023, then surged by 2,249.10% to $21.4 million in 2024, then plummeted by 247.46% to -$60.2 million in 2025.
  • Its Operating Income stands at -$60.2 million for Q3 2025, versus $12.1 million for Q2 2025 and -$10.3 million for Q1 2025.